Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 145

1.

Alprazolam plasma concentrations and treatment response in panic disorder and agoraphobia.

Lesser IM, Lydiard RB, Antal E, Rubin RT, Ballenger JC, DuPont R.

Am J Psychiatry. 1992 Nov;149(11):1556-62.

PMID:
1415824
[PubMed - indexed for MEDLINE]
2.

Plasma alprazolam concentrations. Relation to efficacy and side effects in the treatment of panic disorder.

Greenblatt DJ, Harmatz JS, Shader RI.

Arch Gen Psychiatry. 1993 Sep;50(9):715-22.

PMID:
8357297
[PubMed - indexed for MEDLINE]
3.

Imipramine treatment of panic disorder with agoraphobia: dose ranging and plasma level-response relationships.

Mavissakalian MR, Perel JM.

Am J Psychiatry. 1995 May;152(5):673-82.

PMID:
7726306
[PubMed - indexed for MEDLINE]
4.

A fixed-dose study of alprazolam 2 mg, alprazolam 6 mg, and placebo in panic disorder.

Lydiard RB, Lesser IM, Ballenger JC, Rubin RT, Laraia M, DuPont R.

J Clin Psychopharmacol. 1992 Apr;12(2):96-103.

PMID:
1573046
[PubMed - indexed for MEDLINE]
5.

Double-blind, placebo-controlled study of a once-a-day, sustained-release preparation of alprazolam for the treatment of panic disorder.

Schweizer E, Patterson W, Rickels K, Rosenthal M.

Am J Psychiatry. 1993 Aug;150(8):1210-5.

PMID:
8328566
[PubMed - indexed for MEDLINE]
6.

Maintenance drug treatment of panic disorder. I. Results of a prospective, placebo-controlled comparison of alprazolam and imipramine.

Schweizer E, Rickels K, Weiss S, Zavodnick S.

Arch Gen Psychiatry. 1993 Jan;50(1):51-60.

PMID:
8422222
[PubMed - indexed for MEDLINE]
7.

The relationship of alprazolam dose to steady-state plasma concentrations.

Ciraulo DA, Antal EJ, Smith RB, Olson DR, Goldberg DA, Rand EH, Raskin RB, Phillips JP, Shader RI, Greenblatt DJ.

J Clin Psychopharmacol. 1990 Feb;10(1):27-32.

PMID:
2407754
[PubMed - indexed for MEDLINE]
8.

Adinazolam-SR in panic disorder with agoraphobia: relationship of daily dose to efficacy.

Carter CS, Fawcett J, Hertzman M, Papp LA, Jones W, Patterson WM, Swinson RP, Weise CC, Maddock RJ, Denahan AQ, et al.

J Clin Psychiatry. 1995 May;56(5):202-10.

PMID:
7737960
[PubMed - indexed for MEDLINE]
9.

Discontinuation reactions to alprazolam in panic disorder.

Pecknold JC.

J Psychiatr Res. 1993;27 Suppl 1:155-70.

PMID:
8145176
[PubMed - indexed for MEDLINE]
10.

Pharmacokinetics and clinical effects of alprazolam following single and multiple oral doses in patients with panic disorder.

Ciraulo DA, Barnhill JG, Boxenbaum HG, Greenblatt DJ, Smith RB.

J Clin Pharmacol. 1986 Apr;26(4):292-8.

PMID:
2871050
[PubMed - indexed for MEDLINE]
11.

Cognitive style, alprazolam plasma levels, and treatment response in panic disorder.

Uhlenhuth EH, Starcevic V, Qualls C, Antal EJ, Matuzas W, Javaid JI, Barnhill J.

Depress Anxiety. 2008;25(8):E18-26.

PMID:
17960759
[PubMed - indexed for MEDLINE]
12.

Double-blind, fixed-dose, placebo-controlled study of paroxetine in the treatment of panic disorder.

Ballenger JC, Wheadon DE, Steiner M, Bushnell W, Gergel IP.

Am J Psychiatry. 1998 Jan;155(1):36-42.

PMID:
9433336
[PubMed - indexed for MEDLINE]
13.

Double-blind comparison of alprazolam and adinazolam for panic and phobic disorders.

Pyke RE, Greenberg HS.

J Clin Psychopharmacol. 1989 Feb;9(1):15-21.

PMID:
2651489
[PubMed - indexed for MEDLINE]
14.

A controlled, prospective, 1-year trial of citalopram in the treatment of panic disorder.

Lepola UM, Wade AG, Leinonen EV, Koponen HJ, Frazer J, Sjödin I, Penttinen JT, Pedersen T, Lehto HJ.

J Clin Psychiatry. 1998 Oct;59(10):528-34.

PMID:
9818634
[PubMed - indexed for MEDLINE]
15.

Three-year follow-up of patients with panic disorder after short-term treatment with alprazolam and imipramine.

Lepola UM, Rimón RH, Riekkinen PJ.

Int Clin Psychopharmacol. 1993 Summer;8(2):115-8.

PMID:
8345160
[PubMed - indexed for MEDLINE]
16.

Abrupt discontinuation of alprazolam and cognitive style in patients with panic disorder: early effects on mood, performance, and vital signs.

Uhlenhuth EH, Starcevic V, Qualls C, Antal EJ, Matuzas W, Javaid JI, Barnhill J.

J Clin Psychopharmacol. 2006 Oct;26(5):519-23.

PMID:
16974197
[PubMed - indexed for MEDLINE]
17.

Alprazolam withdrawal in patients with panic disorder and generalized anxiety disorder: vulnerability and effect of carbamazepine.

Klein E, Colin V, Stolk J, Lenox RH.

Am J Psychiatry. 1994 Dec;151(12):1760-6.

PMID:
7977882
[PubMed - indexed for MEDLINE]
18.

Relationship between concentrations of adinazolam and its primary metabolite in plasma and therapeutic/untoward effects in the treatment of panic disorder.

Fleishaker JC, Greist JH, Jefferson JW, Sheridan AQ.

J Clin Psychopharmacol. 1994 Feb;14(1):28-35.

PMID:
8151001
[PubMed - indexed for MEDLINE]
19.

Do antidepressants selectively suppress spontaneous (unexpected) panic attacks? A replication.

Uhlenhuth EH, Matuzas W, Warner TD, Paine S, Lydiard RB, Pollack MH.

J Clin Psychopharmacol. 2000 Dec;20(6):622-7.

PMID:
11106133
[PubMed - indexed for MEDLINE]
20.

Alprazolam in panic disorder and agoraphobia: results from a multicenter trial. II. Patient acceptance, side effects, and safety.

Noyes R Jr, DuPont RL Jr, Pecknold JC, Rifkin A, Rubin RT, Swinson RP, Ballenger JC, Burrows GD.

Arch Gen Psychiatry. 1988 May;45(5):423-8.

PMID:
3358644
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk